8/2/2019 Celgene et. al. v. Actavis South Atlantic
1/95
Charles M. Lizza William C. BatonSAUL EWING LLPOne Riverfront Plaza, Suite 1520Newark, New Jersey 07102-5426(973) 286-6700
[email protected] Attorneys for Plaintiff Celgene Corporation
William J. OShaughnessyJonathan M.H. ShortMCCARTER & ENGLISH , LLPFour Gateway Center100 Mulberry StreetNewark, New Jersey 07102(973) [email protected]
Attorneys for Plaintiffs Novartis PharmaceuticalsCorporation and Novartis Pharma AG
UNITED STATES DISTRICT COURTDISTRICT OF NEW JERSEY
CELGENE CORPORATION, NOVARTISPHARMACEUTICALS CORPORATION
and NOVARTIS PHARMA AG,
Plaintiffs,
v.
ACTAVIS SOUTH ATLANTIC LLC,
Defendant.
)))
))))))))))
Civil Action No. ____________________
COMPLAINT FOR PATENTINFRINGEMENT
(Filed Electronically)
Plaintiffs Celgene Corporation (Celgene), Novartis Pharmaceuticals Corporation and
Novartis Pharma AG, (together, Novartis) (collectively, Plaintiffs), by their attorneys, for
their Complaint against defendant Actavis South Atlantic LLC (Actavis or Defendant),
allege as follows:
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 1 of 95 PageID: 277432
8/2/2019 Celgene et. al. v. Actavis South Atlantic
2/95
- 2 -
Nature of the Action
1. This is an action for patent infringement under the patent laws of the United
States, 35 United States Code, arising from Defendants filing of an Abbreviated New Drug
Application (ANDA) with the United States Food and Drug Administration (FDA) seeking
approval to market a generic version of Novartis patented FOCALIN XR drug product in new,
25 mg and 35 mg dosage strengths prior to the expiration of Celgenes United States Patent Nos.
5,908,850 (the 850 patent), 6,355,656 (the 656 patent), 6,528,530 (the 530 patent),
5,837,284 (the 1998 284 patent), 6,635,284 (the 2003 284 patent), and 7,431,944 (the
944 patent), all of which cover the FOCALIN XR products or their use (collectively, the
Patents-in-Suit).
The Parties
2. Plaintiff Celgene Corporation is a corporation organized and existing under the
laws of the State of Delaware, having a principal place of business at 86 Morris Avenue,
Summit, New Jersey 07901.
3. Plaintiff Novartis Pharmaceuticals Corporation is a corporation organized and
existing under the laws of the State of Delaware, having a principal place of business at 59 Route
10, East Hanover, New Jersey 07936.
4. Plaintiff Novartis Pharma AG is a corporation organized and existing under the
laws of Switzerland, having an office and place of business at Lichtstrasse 35, CH-4056 Basel,
Switzerland.
5. Upon information and belief, Defendant Actavis South Atlantic LLC is a limited
liability company organized and existing under the laws of the state of Delaware, having a
principal place of business at 13800 N.W. 2nd Street, Suite 190, Sunrise, Florida 33325.
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 2 of 95 PageID: 277433
8/2/2019 Celgene et. al. v. Actavis South Atlantic
3/95
- 3 -
6. Actavis initially prepared and filed with the FDA, pursuant to 21 U.S.C. 355(j),
ANDA No. 79-108 concerning proposed generic versions of FOCALIN XR in 5 mg, 10 mg, 15
mg, and 20 mg dosage strengths. Within forty-five (45) days of receiving notice of that ANDA
filing, Celgene and Novartis instituted a lawsuit in this Court captioned Celgene Corporation,
Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Actavis South Atlantic LLC
and Abrika Pharmaceuticals, Inc. , Civil Action No. 07-5367 (FLW)(TJB) (D.N.J.) (the First
Actavis Litigation). Pursuant to a confidential settlement agreement, that matter was resolved
and dismissed without prejudice by this Court on April 22, 2010. The First Actavis Litigation
and the resulting settlement concerned only Actaviss proposed 5 mg, 10 mg, 15 mg, and 20 mgproducts, which were the only dosage strengths included in Actaviss ANDA at the time. After
the First Actavis Litigation was resolved, Actavis informed Celgene and Novartis, via Paragraph
IV notices dated March 1, 2011 and September 20, 2011, that it had amended its ANDA No. 79-
108 to include 30 mg and 40 mg dosage strengths of its proposed generic product. Actaviss 30
mg product is the subject of an action currently pending before this Court captioned Celgene
Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v. Actavis South
Atlantic LLC , Civil Action No. 11-2162 (SDW)(MCA) (D.N.J.), which was filed on April 15,
2011. Actaviss 40 mg product is the subject of an action currently pending before this Court
captioned Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma
AG v. Actavis South Atlantic LLC , Civil Action No. 11-6519 (SDW)(MCA) (D.N.J.), which was
filed on November 4, 2011. The parties recently reached a settlement of the litigations relating
to Actaviss 30 mg and 40 mg products and have submitted the settlement documents for review
by the relevant governmental authorities. ( See Dkt. No. 23 in Civil Action No. 11-2162, and
Dkt. No. 8 in Civil Action No. 11-6519.) By way of a Paragraph IV notice dated February 3,
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 3 of 95 PageID: 277434
8/2/2019 Celgene et. al. v. Actavis South Atlantic
4/95
- 4 -
2012, Actavis informed Celgene and Novartis that it had filed a new ANDA, number 203614,
concerning proposed generic versions of FOCALIN XR in 25 mg and 35 mg dosage strengths
(Actaviss 25 mg and 35 mg Products). The present action concerns Actaviss 25 mg and 35
mg Products and is filed within forty-five (45) days of Plaintiffs receipt of that notice.
7. Upon information and belief, if ANDA No. 203614 is approved, it is the intention
of Actavis to commercially manufacture, use, and sell Actaviss 25 mg and 35 mg Products in
the United States.
Jurisdiction and Venue
8. This Court has jurisdiction over the subject matter of this action pursuant to
28 U.S.C. 1331 and 1338(a).
9. This Court has personal jurisdiction over Actavis because of: i) Actaviss
continuous and systematic contacts with New Jersey ( e.g. , upon information and belief, Actavis
directly, or through its divisions, subsidiaries, agents and/or alter-egos, manufactures, distributes,
markets and sells generic pharmaceutical products, and maintains executive offices and a
manufacturing facility, in this judicial district; ii) The Honorable Susan D. Wigentons May 17,
2007 Order in the matter captioned Celgene Corporation, Novartis Pharmaceuticals
Corporation and Novartis Pharma AG v. Abrika Pharmaceuticals, Inc. and Actavis South
Atlantic LLC , Civil Action No. 06-5818 (SDW)(MCA), finding that Actavis is subject to
personal jurisdiction in the State of New Jersey; iii) Actaviss consent to litigation before this
Court in the First Actavis Litigation specifically concerning Actaviss proposed generic versions
of FOCALIN XR; and iv) Actaviss consent to litigation before this Court in the currently
pending cases captioned Celgene Corporation, Novartis Pharmaceuticals Corporation and
Novartis Pharma AG v. Actavis South Atlantic LLC , Civil Action No. 11-2162 (SDW)(MCA)
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 4 of 95 PageID: 277435
8/2/2019 Celgene et. al. v. Actavis South Atlantic
5/95
- 5 -
(D.N.J.), and Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis
Pharma AG v. Actavis South Atlantic LLC , Civil Action No. 11-6519 (SDW)(MCA) (D.N.J.).
10. Venue is proper in this judicial district pursuant to 28 U.S.C. 1391 and
1400(b).
The Patents-in-Suit and the FOCALIN XR Drug Products
11. The 850 patent, entitled Method of Treating Attention Deficit Disorders With
D-Threo Methylphenidate, duly and legally issued to Celgene on June 1, 1999, by the United
States Patent and Trademark Office (PTO). A copy of the 850 patent is attached hereto as
Exhibit A. The 850 patent includes claims directed to methods of treatment using d-threo
methylphenidate.
12. The 656 patent, entitled Phenidate Drug Formulations Having Diminished
Abuse Potential, originally duly and legally issued to Celgene on March 12, 2002, by the PTO.
An Ex Parte Reexamination Certificate, which amended certain claims of the 656 patent and
added new claims, issued on March 27, 2007, by the PTO. Copies of the 656 patent and the Ex
Parte Reexamination Certificate for the 656 patent are attached hereto as Exhibit B. The 656
patent claims are directed to pharmaceutical unit dosages of d-threo methylphenidate.
13. The 530 patent, entitled Phenidate Drug Formulations Having Diminished
Abuse Potential, duly and legally issued to Celgene on March 4, 2003, by the PTO. A copy of
the 530 patent is attached hereto as Exhibit C. The 530 patent includes claims directed to
pharmaceutical unit dosages of d-threo methylphenidate.
14. The 1998 284 patent, entitled Delivery of Multiple Doses of Medications, duly
and legally issued to Celgene on November 17, 1998, by the PTO. A copy of the 1998 284
patent is attached hereto as Exhibit D. The 1998 284 patent includes claims directed to
extended release dosage forms of methylphenidate drug products.
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 5 of 95 PageID: 277436
8/2/2019 Celgene et. al. v. Actavis South Atlantic
6/95
- 6 -
15. The 2003 284 patent, entitled Delivery of Multiple Doses of Medications, duly
and legally issued to Celgene on October 21, 2003, by the PTO. A copy of the 2003 284 patent
is attached hereto as Exhibit E. The 2003 284 patent includes claims directed to an extended
release dosage form and claims directed to a method of treating disease with certain extended
release dosage forms.
16. The 944 patent, entitled Delivery of Multiple Doses of Medications, duly and
legally issued to Celgene on October 7, 2008, by the PTO. A copy of the 944 patent is attached
hereto as Exhibit F. The 944 patent includes claims directed to dosage forms for oral
administration of a methylphenidate drug.17. Celgene is the owner by assignment of all right, title and interest in the Patents-in-
Suit. Novartis Pharma AG is the exclusive licensee, in certain fields of use, of the Patents-in-
Suit.
18. Novartis Pharmaceuticals Corporation holds an approved New Drug Application
for extended release capsules (including 25 mg and 35 mg dosage strengths) of the hydrochloride
salt of d-threo -methylphenidate, also known as dexmethylphenidate hydrochloride, which it sells
as commercial products under the trade name FOCALIN XR. This commercial product or its
use is covered by one or more claims of the Patents-in-Suit.
Acts Giving Rise To This Action
19. Plaintiffs received a letter from Actavis dated February 3, 2012, (the Notification
Letter), notifying them that Actavis had filed ANDA No. 203614 with the FDA seeking
approval to market 25 mg and 35 mg extended release dexmethylphenidate hydrochloride
capsules. The Notification Letter informed Plaintiffs that Actavis had submitted a certification to
the FDA pursuant to 21 U.S.C. 355(j)(2)(vii)(IV) (Paragraph IV Certification) stating that, in
Actaviss opinion, all claims of the 850 patent, the 656 patent, the 530 patent, the 1998 284
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 6 of 95 PageID: 277437
8/2/2019 Celgene et. al. v. Actavis South Atlantic
7/95
- 7 -
patent, the 2003 284 patent, and the 944 patent are invalid, unenforceable, and/or not infringed
by Actaviss 25 mg and 35 mg Products.
20. Actavis seeks approval to engage in the commercial manufacture, use and sale of
Actaviss 25 mg and 35 mg Products prior to the expiration of the Patents-in-Suit, which are
listed in the FDA publication entitled Approved Drug Products with Therapeutic Equivalence
Evaluations, as being applicable to the patented FOCALIN XR products.
21. Upon information and belief, Actavis intends to engage, and will engage, in the
commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products promptly upon
receiving FDA approval to do so.22. Upon information and belief, Actaviss ANDA No. 203614 contains information
showing that Actaviss 25 mg and 35 mg Products (a) are bioequivalent to the patented
FOCALIN XR products, (b) have the same active ingredient as the patented FOCALIN XR
products, (c) have the same route of administration and strength as the patented FOCALIN XR
products, and (d) have the same, or substantially the same, dosage form and proposed labeling,
and the same indication and usage, as the patented FOCALIN XR products.
23. This action has been brought, pursuant to 21 U.S.C. 355(j)(5)(B)(iii), before the
expiration of forty-five (45) days from the date of receipt by Plaintiffs of the Notification Letter.
Count I: Actaviss Filing of an ANDA for Actaviss 25 mg and 35 mg Products Infringesthe 850 Patent.
24. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
25. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 7 of 95 PageID: 277438
8/2/2019 Celgene et. al. v. Actavis South Atlantic
8/95
- 8 -
expiration of the 850 patent, constitutes infringement of one or more of the claims of that patent
under 35 U.S.C. 271(e)(2)(A).
26. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 850 patent under 35 U.S.C. 271 by making, using, offering to sell,
importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
27. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 850 patent is not enjoined. Plaintiffs do not have an adequate remedy at law
for this infringement.
Count II: Actaviss Filing of an ANDA for Actaviss 25 mg and 35 mg Products Infringesthe 656 Patent.
28. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
29. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 656 patent, constitutes infringement of one or more of the claims of that patent
under 35 U.S.C. 271(e)(2)(A).
30. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 656 patent under 35 U.S.C. 271 by making, using, offering to sell,
importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
31. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 656 patent is not enjoined. Plaintiffs do not have an adequate remedy at law
for this infringement.
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 8 of 95 PageID: 277439
8/2/2019 Celgene et. al. v. Actavis South Atlantic
9/95
- 9 -
Count III: Actaviss Filing of an ANDA for Actaviss 25 mg and 35 mg Products Infringesthe 530 Patent.
32. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
33. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 530 patent, constitutes infringement of one or more of the claims of that patent
under 35 U.S.C. 271(e)(2)(A).
34. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 530 patent under 35 U.S.C. 271 by making, using, offering to sell,
importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
35. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 530 patent is not enjoined. Plaintiffs do not have an adequate remedy at law
for this infringement.
Count IV: Actaviss Filing of an ANDA for Actaviss 25 mg and 35 mg Products Infringes the1998 284 Patent.
36. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
37. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 1998 284 patent, constitutes infringement of one or more of the claims of that
patent under 35 U.S.C. 271(e)(2)(A).
38. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 1998 284 patent under 35 U.S.C. 271 by making, using, offering to
sell, importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 9 of 95 PageID: 277440
8/2/2019 Celgene et. al. v. Actavis South Atlantic
10/95
- 10 -
39. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 1998 284 patent is not enjoined. Plaintiffs do not have an adequate remedy
at law for this infringement.
Count V: Actaviss Filing of the ANDA for Actaviss 25 mg and 35 mg Products Infringesthe 2003 284 Patent.
40. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
41. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 2003 284 patent, constitutes infringement of one or more of the claims of that
patent under 35 U.S.C. 271(e)(2)(A).
42. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 2003 284 patent under 35 U.S.C. 271 by making, using, offering to
sell, importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
43. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 2003 284 patent is not enjoined. Plaintiffs do not have an adequate remedy
at law for this infringement.
Count VI: Actaviss Filing of the ANDA for Actaviss 25 mg and 35 mg Products Infringesthe 944 Patent.
44. Plaintiffs repeat and reallege the allegations of paragraphs 1-23 as though fully set
forth herein.
45. Actaviss submission of ANDA No. 203614 seeking to obtain approval to engage
in the commercial manufacture, use or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 944 patent, constitutes infringement of one or more of the claims of that patent
under 35 U.S.C. 271(e)(2)(A).
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 10 of 95 PageID: 277441
8/2/2019 Celgene et. al. v. Actavis South Atlantic
11/95
- 11 -
46. Unless enjoined by this Court, upon FDA approval of ANDA No. 203614,
Actavis will infringe the 944 patent under 35 U.S.C. 271 by making, using, offering to sell,
importing, or selling Actaviss 25 mg and 35 mg Products in the United States.
47. Plaintiffs will be substantially and irreparably damaged and harmed if Actaviss
infringement of the 944 patent is not enjoined. Plaintiffs do not have an adequate remedy at law
for this infringement.
Prayer For Relief
WHEREFORE, Plaintiffs respectfully request the following relief:
(A) A Judgment declaring that Actavis has infringed one or more claims of the 850
patent;
(B) A Judgment declaring that Actavis has infringed one or more claims of the 656
patent;
(C) A Judgment declaring that Actavis has infringed one or more claims of the 530
patent;
(D) A Judgment declaring that Actavis has infringed one or more claims of the 1998
284 patent;
(E) A Judgment declaring that Actavis has infringed one or more claims of the 2003
284 patent;
(F) A Judgment declaring that Actavis has infringed one or more claims of the 944
patent;
(G) An Order that the effective date of any FDA approval of ANDA No. 203614, with
respect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 850 patent, or any expiration of exclusivity to which Plaintiffs are or become
entitled;
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 11 of 95 PageID: 277442
8/2/2019 Celgene et. al. v. Actavis South Atlantic
12/95
- 12 -
(H) An Order that the effective date of any FDA approval of ANDA No. 203614, with
respect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 656 patent, or any expiration of exclusivity to which Plaintiffs are or become
entitled;
(I) An Order that the effective date of any FDA approval of ANDA No. 203614, with
respect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 530 patent, or any expiration of exclusivity to which Plaintiffs are or become
entitled;
(J)
An Order that the effective date of any FDA approval of ANDA No. 203614, withrespect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 1998 284 patent, or any expiration of exclusivity to which Plaintiffs are or
become entitled;
(K) An Order that the effective date of any FDA approval of ANDA No. 203614, with
respect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 2003 284 patent, or any expiration of exclusivity to which Plaintiffs are or
become entitled;
(L) An Order that the effective date of any FDA approval of ANDA No. 203614, with
respect to Actaviss 25 mg and 35 mg Products, be a date which is not earlier than the later of the
expiration of the 944 patent, or any expiration of exclusivity to which Plaintiffs are or become
entitled;
(M) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
attorneys and employees, and those acting in privity or concert with them, from making, using,
selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 12 of 95 PageID: 277443
8/2/2019 Celgene et. al. v. Actavis South Atlantic
13/95
- 13 -
until after the expiration of the 850 patent, or any expiration of exclusivity to which Plaintiffs
are or become entitled;
(N) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
attorneys and employees, and those acting in privity or concert with them, from making, using,
selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
until after the expiration of the 656 patent, or any expiration of exclusivity to which Plaintiffs
are or become entitled;
(O) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
attorneys and employees, and those acting in privity or concert with them, from making, using,selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
until after the expiration of the 530 patent, or any expiration of exclusivity to which Plaintiffs
are or become entitled;
(P) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
attorneys and employees, and those acting in privity or concert with them, from making, using,
selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
until after the expiration of the 1998 284 patent, or any expiration of exclusivity to which
Plaintiffs are or become entitled;
(Q) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
attorneys and employees, and those acting in privity or concert with them, from making, using,
selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
until after the expiration of the 2003 284 patent, or any expiration of exclusivity to which
Plaintiffs are or become entitled;
(R) Preliminary and permanent injunctions enjoining Actavis and its officers, agents,
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 13 of 95 PageID: 277444
8/2/2019 Celgene et. al. v. Actavis South Atlantic
14/95
- 14 -
attorneys and employees, and those acting in privity or concert with them, from making, using,
selling, offering to sell, or importing into the United States Actaviss 25 mg and 35 mg Products
until after the expiration of the 944 patent, or any expiration of exclusivity to which Plaintiffs
are or become entitled;
(S) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe or
induce and/or contribute to infringement of the 850 patent;
(T) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe orinduce and/or contribute to infringement of the 656 patent;
(U) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe or
induce and/or contribute to infringement of the 530 patent;
(V) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe or
induce and/or contribute to infringement of the 1998 284 patent;
(W) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe or
induce and/or contribute to infringement of the 2003 284 patent;
(X) A Declaration that the commercial manufacture, use, importation into the United
States, sale or offering for sale of Actaviss 25 mg and 35 mg Products will directly infringe or
induce and/or contribute to infringement of the 944 patent;
(Y) If Actavis engages in the commercial manufacture, use, importation into the
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 14 of 95 PageID: 277445
8/2/2019 Celgene et. al. v. Actavis South Atlantic
15/95
- 15 -
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 850 patent, a Judgment awarding damages to Plaintiffs resulting from such
infringement, increased to treble the amount found or assessed, together with interest;
(Z) If Actavis engages in the commercial manufacture, use, importation into the
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 656 patent, a Judgment awarding damages to Plaintiffs resulting from such
infringement, increased to treble the amount found or assessed, together with interest;
(AA) If Actavis engages in the commercial manufacture, use, importation into the
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to theexpiration of the 530 patent, a Judgment awarding damages to Plaintiffs resulting from such
infringement, increased to treble the amount found or assessed, together with interest;
(BB) If Actavis engages in the commercial manufacture, use, importation into the
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 1998 284 patent, a Judgment awarding damages to Plaintiffs resulting from
such infringement, increased to treble the amount found or assessed, together with interest;
(CC) If Actavis engages in the commercial manufacture, use, importation into the
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 2003 284 patent, a Judgment awarding damages to Plaintiffs resulting from
such infringement, increased to treble the amount found or assessed, together with interest;
(DD) If Actavis engages in the commercial manufacture, use, importation into the
United States, offering to sell, or sale of Actaviss 25 mg and 35 mg Products prior to the
expiration of the 944 patent, a Judgment awarding damages to Plaintiffs resulting from such
infringement, increased to treble the amount found or assessed, together with interest;
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 15 of 95 PageID: 277446
8/2/2019 Celgene et. al. v. Actavis South Atlantic
16/95
- 16 -
(EE) A Judgment that this is an exceptional case pursuant to 35 U.S.C. 271(e)(4)
and 285, entitling Plaintiffs to their reasonable attorneys fees;
(FF) Costs and expenses in this action; and
(GG) Such further and other relief as this Court may deem just and proper.
Dated: March 16, 2012 Respectfully submitted,
By: s/ William J. OShaughnessyWilliam J. OShaughnessyJonathan M.H. ShortMCCARTER & ENGLISH , LLPFour Gateway Center100 Mulberry StreetNewark, New Jersey 07102(973) 639-2094 [email protected]
By: s/ Charles M. Lizza . Charles M. LizzaWilliam C. BatonSAUL EWING LLPOne Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426(973) [email protected]
OF COUNSEL:
Henry J. Renk Tara A. ByrneFITZPATRICK , CELLA , HARPER & SCINTO 1290 Avenue of the AmericasNew York, New York 10104(212) 218-2100
Attorneys for Plaintiffs Novartis Pharmaceuticals Corporationand Novartis Pharma AG
OF COUNSEL:
Anthony M. InsognaRichard D. WhitlowJONES DAY 12265 El Camino Real, Suite 200San Diego, California 92130-4096(858) 314-1200
Jason G. WinchesterJONES DAY 77 West WackerChicago, Illinois 60601-1692(312) 782-3939
Attorneys for Plaintiff Celgene Corporation
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 16 of 95 PageID: 277447
8/2/2019 Celgene et. al. v. Actavis South Atlantic
17/95
- 17 -
CERTIFICATION PURSUANT TO L. CIV. R. 11.2 & 40.1
I hereby certify that the matters captioned, (i) Celgene Corporation, Novartis
Pharmaceuticals Corporation and Novartis Pharma AG v. Actavis South Atlantic LLC , Civil
Action No. 11-2162 (SDW)(MCA) (D.N.J.), (ii) Celgene Corporation, Novartis
Pharmaceuticals Corporation and Novartis Pharma AG v. Actavis South Atlantic LLC , Civil
Action No. 11-6519 (SDW)(MCA) (D.N.J.), (iii) Celgene Corporation, Novartis
Pharmaceuticals Corporation and Novartis Pharma AG v. IntelliPharmaCeutics Corp. , Civil
Action No. 11-1736 (ES)(CLW) (D.N.J.), (iv) Celgene Corporation, Novartis Pharmaceuticals
Corporation and Novartis Pharma AG v. Teva Pharmaceuticals USA, Inc. , Civil Action No. 11-2356 (SDW)(MCA) (D.N.J.), (v) Celgene Corporation, Novartis Pharmaceuticals Corporation
and Novartis Pharma AG v. Par Pharmaceutical, Inc. , Civil Action No. 11-3094 (SDW)(MCA)
(D.N.J.), (vi) Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis
Pharma AG v. Par Pharmaceutical, Inc. , Civil Action No. 11-6640 (SDW)(MCA) (D.N.J.), and
(vii) Celgene Corporation, Novartis Pharmaceuticals Corporation and Novartis Pharma AG v.
Teva Pharmaceuticals USA, Inc. , Civil Action No. 11-7064 (SDW)(MCA) (D.N.J.), are related
to the matter in controversy because the matter in controversy involves the same Plaintiffs and
the same six patents.
I further certify that, to the best of my knowledge, the matter in controversy is not the
subject of any other action pending in any court, or of any pending arbitration or administrative
proceeding.
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 17 of 95 PageID: 277448
8/2/2019 Celgene et. al. v. Actavis South Atlantic
18/95
- 18 -
Dated: March 16, 2012 Respectfully submitted,
By: s/ William J. OShaughnessyWilliam J. OShaughnessyJonathan M.H. ShortMCCARTER & ENGLISH , LLPFour Gateway Center100 Mulberry StreetNewark, New Jersey 07102(973) 639-2094 [email protected]
By: s/ Charles M. Lizza . Charles M. LizzaWilliam C. Baton
SAUL EWING LLPOne Riverfront Plaza, Suite 1520Newark, New Jersey 07102-5426(973) [email protected]
OF COUNSEL:
Henry J. Renk Tara A. ByrneFITZPATRICK , CELLA , HARPER & SCINTO 1290 Avenue of the AmericasNew York, New York 10104(212) 218-2100
Attorneys for Plaintiffs Novartis Pharmaceuticals Corporationand Novartis Pharma AG
OF COUNSEL:
Anthony M. InsognaRichard D. WhitlowJONES DAY 12265 El Camino Real, Suite 200San Diego, California 92130-4096(858) 314-1200
Jason G. WinchesterJONES DAY 77 West WackerChicago, Illinois 60601-1692(312) 782-3939
Attorneys for Plaintiff Celgene Corporation
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 18 of 95 PageID: 277449
8/2/2019 Celgene et. al. v. Actavis South Atlantic
19/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 19 of 95 PageID: 277450
8/2/2019 Celgene et. al. v. Actavis South Atlantic
20/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 20 of 95 PageID: 277451
8/2/2019 Celgene et. al. v. Actavis South Atlantic
21/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 21 of 95 PageID: 277452
8/2/2019 Celgene et. al. v. Actavis South Atlantic
22/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 22 of 95 PageID: 277453
8/2/2019 Celgene et. al. v. Actavis South Atlantic
23/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 23 of 95 PageID: 277454
8/2/2019 Celgene et. al. v. Actavis South Atlantic
24/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 24 of 95 PageID: 277455
8/2/2019 Celgene et. al. v. Actavis South Atlantic
25/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 25 of 95 PageID: 277456
8/2/2019 Celgene et. al. v. Actavis South Atlantic
26/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 26 of 95 PageID: 277457
8/2/2019 Celgene et. al. v. Actavis South Atlantic
27/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 27 of 95 PageID: 277458
8/2/2019 Celgene et. al. v. Actavis South Atlantic
28/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 28 of 95 PageID: 277459
8/2/2019 Celgene et. al. v. Actavis South Atlantic
29/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 29 of 95 PageID: 277460
8/2/2019 Celgene et. al. v. Actavis South Atlantic
30/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 30 of 95 PageID: 277461
8/2/2019 Celgene et. al. v. Actavis South Atlantic
31/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 31 of 95 PageID: 277462
8/2/2019 Celgene et. al. v. Actavis South Atlantic
32/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 32 of 95 PageID: 277463
8/2/2019 Celgene et. al. v. Actavis South Atlantic
33/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 33 of 95 PageID: 277464
8/2/2019 Celgene et. al. v. Actavis South Atlantic
34/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 34 of 95 PageID: 277465
8/2/2019 Celgene et. al. v. Actavis South Atlantic
35/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 35 of 95 PageID: 277466
8/2/2019 Celgene et. al. v. Actavis South Atlantic
36/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 36 of 95 PageID: 277467
8/2/2019 Celgene et. al. v. Actavis South Atlantic
37/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 37 of 95 PageID: 277468
8/2/2019 Celgene et. al. v. Actavis South Atlantic
38/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 38 of 95 PageID: 277469
8/2/2019 Celgene et. al. v. Actavis South Atlantic
39/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 39 of 95 PageID: 277470
8/2/2019 Celgene et. al. v. Actavis South Atlantic
40/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 40 of 95 PageID: 277471
8/2/2019 Celgene et. al. v. Actavis South Atlantic
41/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 41 of 95 PageID: 277472
8/2/2019 Celgene et. al. v. Actavis South Atlantic
42/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 42 of 95 PageID: 277473
8/2/2019 Celgene et. al. v. Actavis South Atlantic
43/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 43 of 95 PageID: 277474
8/2/2019 Celgene et. al. v. Actavis South Atlantic
44/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 44 of 95 PageID: 277475
8/2/2019 Celgene et. al. v. Actavis South Atlantic
45/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 45 of 95 PageID: 277476
8/2/2019 Celgene et. al. v. Actavis South Atlantic
46/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 46 of 95 PageID: 277477
8/2/2019 Celgene et. al. v. Actavis South Atlantic
47/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 47 of 95 PageID: 277478
8/2/2019 Celgene et. al. v. Actavis South Atlantic
48/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 48 of 95 PageID: 277479
8/2/2019 Celgene et. al. v. Actavis South Atlantic
49/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 49 of 95 PageID: 277480
8/2/2019 Celgene et. al. v. Actavis South Atlantic
50/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 50 of 95 PageID: 277481
8/2/2019 Celgene et. al. v. Actavis South Atlantic
51/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 51 of 95 PageID: 277482
8/2/2019 Celgene et. al. v. Actavis South Atlantic
52/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 52 of 95 PageID: 277483
8/2/2019 Celgene et. al. v. Actavis South Atlantic
53/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 53 of 95 PageID: 277484
8/2/2019 Celgene et. al. v. Actavis South Atlantic
54/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 54 of 95 PageID: 277485
8/2/2019 Celgene et. al. v. Actavis South Atlantic
55/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 55 of 95 PageID: 277486
8/2/2019 Celgene et. al. v. Actavis South Atlantic
56/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 56 of 95 PageID: 277487
8/2/2019 Celgene et. al. v. Actavis South Atlantic
57/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 57 of 95 PageID: 277488
8/2/2019 Celgene et. al. v. Actavis South Atlantic
58/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 58 of 95 PageID: 277489
8/2/2019 Celgene et. al. v. Actavis South Atlantic
59/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 59 of 95 PageID: 277490
8/2/2019 Celgene et. al. v. Actavis South Atlantic
60/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 60 of 95 PageID: 277491
8/2/2019 Celgene et. al. v. Actavis South Atlantic
61/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 61 of 95 PageID: 277492
8/2/2019 Celgene et. al. v. Actavis South Atlantic
62/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 62 of 95 PageID: 277493
8/2/2019 Celgene et. al. v. Actavis South Atlantic
63/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 63 of 95 PageID: 277494
8/2/2019 Celgene et. al. v. Actavis South Atlantic
64/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 64 of 95 PageID: 277495
8/2/2019 Celgene et. al. v. Actavis South Atlantic
65/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 65 of 95 PageID: 277496
8/2/2019 Celgene et. al. v. Actavis South Atlantic
66/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 66 of 95 PageID: 277497
8/2/2019 Celgene et. al. v. Actavis South Atlantic
67/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 67 of 95 PageID: 277498
8/2/2019 Celgene et. al. v. Actavis South Atlantic
68/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 68 of 95 PageID: 277499
8/2/2019 Celgene et. al. v. Actavis South Atlantic
69/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 69 of 95 PageID: 277500
8/2/2019 Celgene et. al. v. Actavis South Atlantic
70/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 70 of 95 PageID: 277501
8/2/2019 Celgene et. al. v. Actavis South Atlantic
71/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 71 of 95 PageID: 277502
8/2/2019 Celgene et. al. v. Actavis South Atlantic
72/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 72 of 95 PageID: 277503
8/2/2019 Celgene et. al. v. Actavis South Atlantic
73/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 73 of 95 PageID: 277504
8/2/2019 Celgene et. al. v. Actavis South Atlantic
74/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 74 of 95 PageID: 277505
8/2/2019 Celgene et. al. v. Actavis South Atlantic
75/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 75 of 95 PageID: 277506
8/2/2019 Celgene et. al. v. Actavis South Atlantic
76/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 76 of 95 PageID: 277507
8/2/2019 Celgene et. al. v. Actavis South Atlantic
77/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 77 of 95 PageID: 277508
8/2/2019 Celgene et. al. v. Actavis South Atlantic
78/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 78 of 95 PageID: 277509
8/2/2019 Celgene et. al. v. Actavis South Atlantic
79/95
EXHIBIT F
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 79 of 95 PageID: 277510
8/2/2019 Celgene et. al. v. Actavis South Atlantic
80/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 80 of 95 PageID: 277511
8/2/2019 Celgene et. al. v. Actavis South Atlantic
81/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 81 of 95 PageID: 277512
8/2/2019 Celgene et. al. v. Actavis South Atlantic
82/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 82 of 95 PageID: 277513
8/2/2019 Celgene et. al. v. Actavis South Atlantic
83/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 83 of 95 PageID: 277514
8/2/2019 Celgene et. al. v. Actavis South Atlantic
84/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 84 of 95 PageID: 277515
8/2/2019 Celgene et. al. v. Actavis South Atlantic
85/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 85 of 95 PageID: 277516
8/2/2019 Celgene et. al. v. Actavis South Atlantic
86/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 86 of 95 PageID: 277517
8/2/2019 Celgene et. al. v. Actavis South Atlantic
87/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 87 of 95 PageID: 277518
8/2/2019 Celgene et. al. v. Actavis South Atlantic
88/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 88 of 95 PageID: 277519
8/2/2019 Celgene et. al. v. Actavis South Atlantic
89/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 89 of 95 PageID: 277520
8/2/2019 Celgene et. al. v. Actavis South Atlantic
90/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 90 of 95 PageID: 277521
8/2/2019 Celgene et. al. v. Actavis South Atlantic
91/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 91 of 95 PageID: 277522
8/2/2019 Celgene et. al. v. Actavis South Atlantic
92/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 92 of 95 PageID: 277523
8/2/2019 Celgene et. al. v. Actavis South Atlantic
93/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 93 of 95 PageID: 277524
8/2/2019 Celgene et. al. v. Actavis South Atlantic
94/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 94 of 95 PageID: 277525
8/2/2019 Celgene et. al. v. Actavis South Atlantic
95/95
Case 2:33-av-00001 Document 14408 Filed 03/16/12 Page 95 of 95 PageID: 277526
Top Related